This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tanezumab In Osteoarthritis Of The Knee (2)

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: January 23, 2009
Last updated: June 7, 2011
Last verified: June 2011
The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis.

Condition Intervention Phase
Arthritis Osteoarthritis Biological: tanezumab 10 mg Biological: tanezumab 5 mg Drug: naproxen Other: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • WOMAC function [ Time Frame: weeks 12 and 16 ]
  • WOMAC pain [ Time Frame: weeks 12 and 16 ]
  • Patient Global Assessment of Osteoarthritis [ Time Frame: weeks 12 and 16 ]

Secondary Outcome Measures:
  • Womac physical function [ Time Frame: weeks 2, 4, 8, 12 and 16 ]
  • Womac pain [ Time Frame: weeks 2, 4, 8, 12 and 16 ]
  • Patient Global Assessment of Osteoarthritis [ Time Frame: weeks 2, 4, 8, 12 and 16 ]
  • OMERACT-OARSI responder criteria [ Time Frame: weeks 2, 4, 8, 12 and 16 ]
  • SF-36 [ Time Frame: weeks 12 and 16 ]
  • Daily NRS scores [ Time Frame: weeks 2, 4, 8, 12 and 16 ]
  • Safety (AEs, laboratory, ECGs, PEs, vital signs) [ Time Frame: all weeks ]
  • Time to discontinuation [ Time Frame: all weeks ]
  • Womac stiffness [ Time Frame: weeks 2, 4, 8, 12 and 16 ]
  • Treatment Response: Reduction in the WOMAC Pain subscale [ Time Frame: weeks 2, 4, 8, 12 and 16 ]

Enrollment: 848
Study Start Date: May 2009
Study Completion Date: July 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Biological: tanezumab 10 mg
tanezumab 10 mg one dose at weeks 0 and 8
Experimental: 2 Biological: tanezumab 5 mg
tanezumab 5 mg one dose at weeks 0 and 8
Active Comparator: 3 Drug: naproxen
naproxen 1000 mg daily for 16 weeks
Placebo Comparator: 4 Other: placebo
placebo to match tanezumab and naproxen dosing


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Osteoarthritis of the knee according to Kellgren-Lawrence x-ray grade of 2

Exclusion Criteria:

  • Pregnancy or intent to become pregnant
  • BMI greater than 39
  • other severe pain, significant cardiac, neurologic or cardiac disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00830063

  Show 85 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00830063     History of Changes
Other Study ID Numbers: A4091015
Study First Received: January 23, 2009
Last Updated: June 7, 2011

Keywords provided by Pfizer:
monoclonal antibody
nerve growth factor
anti-nerve growth factor

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017